Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SBFMW
Upturn stock ratingUpturn stock rating

Sunshine Biopharma Inc. Warrant (SBFMW)

Upturn stock ratingUpturn stock rating
$0.28
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: SBFMW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.28
high$

Analysis of Past Performance

Type Stock
Historic Profit -100%
Avg. Invested days 18
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.96
52 Weeks Range 0.05 - 0.98
Updated Date 05/25/2025
52 Weeks Range 0.05 - 0.98
Updated Date 05/25/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.21

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -13.88%
Operating Margin (TTM) -14.56%

Management Effectiveness

Return on Assets (TTM) -11.78%
Return on Equity (TTM) -21.17%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 4553895
Shares Outstanding -
Shares Floating 4553895
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Sunshine Biopharma Inc. Warrant

stock logo

Company Overview

overview logo History and Background

Sunshine Biopharma Inc. is focused on the research and development of oncology and antiviral drugs. The warrant is a derivative security linked to the underlying common stock. The warrant details are dependent on the warrant offering and should be specifically referenced from the warrant prospectus.

business area logo Core Business Areas

  • Pharmaceutical Research and Development: Focus on developing therapeutics for oncology and antiviral applications.
  • Drug Commercialization: Bringing developed drugs to market, typically through partnerships or direct sales.

leadership logo Leadership and Structure

The leadership team typically includes a CEO, CSO, and CFO. The organizational structure is likely hierarchical with departments focused on research, development, and administration.

Top Products and Market Share

overview logo Key Offerings

  • Adva-27a: A small molecule compound being developed for the treatment of various cancers. It is in preclinical or early clinical stages. Market share is currently negligible as the product is not yet commercialized. Competitors include established cancer therapies and companies developing similar novel oncology drugs.
  • mRNA-based therapeutics: Developing mRNA-based therapies, potentially for cancer or other diseases. Market share is negligible as the product is pre-commercial. Competitors are established players like Moderna and BioNTech in the mRNA space.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive and regulated. Significant investment is required for research and development. Cancer and antiviral drug markets are substantial and growing.

Positioning

Sunshine Biopharma is a small player in the pharmaceutical industry, focused on niche areas of oncology and antiviral research. Its competitive advantage lies in its proprietary drug candidates. The TAM is large, but Sunshine Biopharma currently captures a very small portion due to its development stage.

Total Addressable Market (TAM)

The global oncology and antiviral drug markets are worth hundreds of billions of dollars. Sunshine Biopharma aims to capture a portion of this market. It is positioned as a research company.

Upturn SWOT Analysis

Strengths

  • Proprietary drug candidates
  • Focus on specific therapeutic areas
  • Potential for breakthrough therapies

Weaknesses

  • Limited financial resources
  • Early-stage development pipeline
  • Dependence on partnerships for commercialization

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Successful clinical trial outcomes
  • Expansion into new therapeutic areas

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established players
  • Funding challenges

Competitors and Market Share

competitor logo Key Competitors

  • MRNA
  • PFE
  • JNJ
  • GILD

Competitive Landscape

Sunshine Biopharma operates in a highly competitive landscape dominated by larger, well-established pharmaceutical companies. It must rely on innovation and strategic partnerships to compete effectively.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to its research-focused nature.

Future Projections: Future growth depends on successful clinical trials and commercialization of its drug candidates. Analyst estimates are needed to forecast future revenue and earnings.

Recent Initiatives: Recent initiatives may include clinical trial advancements, partnerships, and fundraising activities.

Summary

Sunshine Biopharma is a small, early-stage pharmaceutical company focused on oncology and antiviral research. Its strengths lie in its proprietary drug candidates, but it faces challenges due to limited resources and competition. Successful clinical trials and strategic partnerships are crucial for its future growth.The warrants' value is tied to the underlying common stock, so it is important to understand the risks and opportunities surrounding the company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC filings
  • Company website
  • Third-party financial analysis reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Sunshine Biopharma Inc. Warrant

Exchange NASDAQ
Headquaters Fort Lauderdale, FL, United States
IPO Launch date 2022-02-15
Chairman, President & CEO Dr. Steve N. Slilaty Ph.D.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 52
Full time employees 52

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.